February 2025 Hims & Hers oral semaglutide controversy: Strive manufactured the oral compounded semaglutide pill that Hims & Hers launched on February 5, 2025, using what Strive described as liposomal technology. Hims pulled the product two days after launch after coming under federal scrutiny
But be aware that non-surgical methods will not likely achieve the same results that surgery would
Because appetite falls, most people take in fewer calories without consciously trying, and that gap is what produces weight change over months
The truth is simple: Belly fat reduces when your body learns to burn fat efficiently
Side effects are generally mild and may include headaches, flushing, or temporary irritation at the injection site
For suspected DVT without breathing difficulties, contact your healthcare provider the same day for urgent assessment